Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Operating Margin (2021 - 2025)

Historic Operating Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 3827.4%.

  • Aligos Therapeutics' Operating Margin fell 22169200.0% to 3827.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 3306.67%, marking a year-over-year decrease of 14201900.0%. This contributed to the annual value of 2468.96% for FY2024, which is 15252100.0% down from last year.
  • Aligos Therapeutics' Operating Margin amounted to 3827.4% in Q3 2025, which was down 22169200.0% from 1924.04% recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Operating Margin peaked at 445.76% during Q2 2023, and registered a low of 10340.05% during Q4 2021.
  • Over the past 5 years, Aligos Therapeutics' median Operating Margin value was 1913.59% (recorded in 2021), while the average stood at 2455.34%.
  • Per our database at Business Quant, Aligos Therapeutics' Operating Margin skyrocketed by 96987800bps in 2022 and then crashed by -30108000bps in 2025.
  • Over the past 5 years, Aligos Therapeutics' Operating Margin (Quarter) stood at 10340.05% in 2021, then soared by 94bps to 641.28% in 2022, then plummeted by -102bps to 1294.03% in 2023, then crashed by -162bps to 3393.23% in 2024, then decreased by -13bps to 3827.4% in 2025.
  • Its Operating Margin stands at 3827.4% for Q3 2025, versus 1924.04% for Q2 2025 and 6187.46% for Q1 2025.